Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR-002: Zanzalintinib in Advanced Solid Tumors
NCT05176483Phase 1Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Dec 2021
- Primary completion
- Jan 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 1, open-label trial of zanzalintinib in solid tumor, renal cell carcinoma (RCC), prostate cancer (PCa) and 5 more (9 arms), sponsored by Exelixis, Inc. Primary endpoints: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) at 36 months, Objective Response Rate at 24 months and 5 more. Started Dec 2021; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
solid tumorrenal cell carcinoma (RCC)prostate cancer (PCa)urothelial carcinoma (UC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05176483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176483.